ClinicalTrials.gg
TerminatedNCT02871297Updated Dec 28, 2022Results posted

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

A Phase 3 interventional study of Vortioxetine in Depressive Disorder, Major, sponsored by H. Lundbeck A/S. Terminated at 78 sites in 20 countries. Open to participants aged 7 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-12-28.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated based on new efficacy data from another study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
662
Allocation
Not applicable
Ages
7 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
7th of 54
662 · median 413
Started
2016
with 8 others
Phase 3
31 of 54
1 open now
Registered
37th of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 7th largest by enrollment, is one of 9 that started in 2016, is one of 31 in phase 3, and was the 37th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 7 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD.

03

Conditions studied

  • Depressive Disorder, Major

Keywords

  • adolescent
  • children
04

Who can participate

Ages eligible
7 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is a male or female child aged ≥7 and \<12 years or adolescent aged ≥12 and ≤18 years in the lead-in study (12709A and 12710A).
  • The participant must have completed Study 12709A or 12710A (Visit 12, Completion Visit) immediately prior to enrolment into this extension study.
  • The participant had a primary diagnosis of MDD at entry in study 12709A or 12710A, diagnosed according to ™.
  • The participant is indicated for long-term treatment with vortioxetine according to the clinical opinion of the Investigator.
  • For participants aged ≥7 and ≤17 years at the Baseline visit; the participant is able to understand the Informed Assent Form, and parent(s)/legal representative(s) are able to read and understand the Form.
  • For participants who turned 18 years during the lead-in study 12710A; the participant has signed the Informed Consent Form.

Exclusion criteria

Exclusion Criteria:

  • The participant has been diagnosed with another psychiatric disorder (for example mania, bipolar disorder, schizophrenia or any psychotic disorder) during study 12709A or 12710A.
  • The participant has an attention-deficit/hyperactivity disorder (ADHD) that requires a pharmacological treatment other than a stimulant medication.

Other protocol-defined inclusion and exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
662 participants (actual)

Study arms

  • Experimental
    Vortioxetine

    Vortioxetine tablets for 26 weeks. Single dose of vortioxetine oral drops (only a subset of participants).

    Drug: Vortioxetine

Interventions

  • Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day.

    Also known as: Brintellix (R), Lu AA21004

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. SAEs included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAE was defined as an AE that started or increased in intensity on or after the date of first dose of study drug in this study 12712A. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.

    Time frame: Baseline up to Week 30

Secondary outcomes

  1. Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 26

    CDRS-R consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. Total score ranged from 17 (normal) to 113 (severe depression). Least square (LS) mean was calculated using a restricted maximum likelihood-based mixed model for repeated measurements (MMRM) approach.

    Time frame: Baseline, Week 26

  2. Time to First Relapse

    Relapse was defined as a total score ≥40 on the CDRS-R. CDRS-R consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. Total score ranged from 17 (normal) to 113 (severe depression).

    Time frame: Baseline up to Week 26

  3. Time to First Loss of Remission

    Remission was defined as a total score ≤28 on the CDRS-R. CDRS-R consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. Total score ranged from 17 (normal) to 113 (severe depression).

    Time frame: Baseline up to Week 26

  4. Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 26

    The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants). LS mean was calculated using a restricted maximum likelihood-based MMRM approach.

    Time frame: Baseline, Week 26

  5. Clinical Global Impression - Global Improvement (CGI-I) Score

    The CGI-I provides the clinician's impression of the participant's improvement (or worsening). The clinician assesses the participant's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). LS mean was calculated using a restricted maximum likelihood-based MMRM approach.

    Time frame: Week 26

  6. Children (7-11 Years): Change From Baseline in Behaviour Rating Inventory of Executive Function - Preschool (BRIEF-P) Using the Global Executive Composite (GEC) Score at Week 26

    BRIEF form is an 86-item measure with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. For BRIEF-P form, only the first 72 items (Inhibit \[10\], Shift \[8\], Emotional Control \[10\], Initiate \[8\], Working Memory \[10\], Plan/Organize \[12\], Organization of Materials \[6\], Monitor \[8\]) were included in clinical scales. Clinical scales combined to form 2 indexes, Behavioural Regulation Index (BRI) and Metacognition Index (MI), and 1 composite summary score, the GEC, that incorporates all 8 clinical scales. GEC score was calculated as the sum of index scores ranging from 72-216; higher scores indicating greater impairment in executive functions. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-P. Conversion was based on gender and age group. T-scores ranged between 30 to 101, with a lower score indicating better functioning.

    Time frame: Baseline, Week 26

  7. Adolescents (12-18 Years): Change From Baseline in Behaviour Rating Inventory of Executive Function - Self-report (BRIEF-SR) Using the GEC Score at Week 26

    BRIEF form is an 86-item measure that assesses impairment in executive function with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. For BRIEF-SR form, only 80 items (Inhibit \[13\], Shift \[10\], Emotional Control \[10\], Initiate \[5\], Working Memory \[12\], Plan/Organize \[13\], Organization of Materials \[7\], Monitor \[10\]) were included in clinical scales. Clinical scales combined to form 2 indexes, the BRI and the MI, and 1 composite summary score, the GEC, that incorporates all 8 clinical scales. GEC score was calculated as the sum of index scores and ranges from 80-240 with higher scores indicating greater impairment in functions. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-SR. The conversion was based on gender and the age group. T-scores ranged between 29 to 104, with a lower score indicating better functioning.

    Time frame: Baseline, Week 26

  8. Children (7-11 Years): Change From Baseline in BRIEF-P Using the MI Score at Week 26

    BRIEF form is an 86-item measure that assesses impairment in executive function with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. Clinical scales combined to form 2 indexes, the BRI and the MI. For BRIEF-P, MI is comprised of Initiate (8), Working Memory (10), Plan/Organize (12), Organization of Materials (6), and Monitor (8) scales. The MI scores are calculated as the sum of the total 44 items ranging from 44 to 132 with lower scores reflecting better functioning. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-P. The conversion was based on gender and the age group. T-scores ranged between 30 to 98, with a lower score indicating better functioning.

    Time frame: Baseline, Week 26

  9. Adolescents (12-18 Years): Change From Baseline in BRIEF-SR Using the MI Score at Week 26

    BRIEF form is an 86-item measure that assesses impairment in executive function with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. Clinical scales combined to form 2 indexes, the BRI and the MI. For BRIEF-SR, MI is comprised of Working Memory (12), Plan/Organize (13), Organization of Materials (7), and Task Completion (10) scales. The MI scores are calculated as the sum of the total 42 items ranging from 42 to 126 with lower scores reflecting better functioning. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-SR. The conversion was based on gender and the age group. T-scores ranged between 31 to 100, with a lower score indicating better functioning.

    Time frame: Baseline, Week 26

  10. Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Week 26

    The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally-oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The score ranges from 1 (most functionally impaired child) to 100 (the healthiest). A score greater than 70 indicates normal function.

    Time frame: Baseline, Week 26

  11. Change From Baseline in Pediatric Quality of Life Inventory Present Functioning Visual Analogue Scale (PedsQL VAS) Total Score at Week 26

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using VAS. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The total score is the average of all 6 items ranging from 0 to 10, where a lower value represents a better outcome.

    Time frame: Baseline, Week 26

  12. Number of Participants With Response to the Palatability Questionnaire

    The palatability of vortioxetine oral drops was assessed after intake of a single dose (5 to 20 mg) corresponding to the participant's current vortioxetine dose (replacing the vortioxetine tablet on that day). The palatability assessment included 4 questions on the overall appreciation of a medicinal product in relation to its taste (What do you think of the taste), mouthfeel (How does medicine feel in your mouth), aftertaste (What do you think of the after taste), and smell (What do you think of the smell). The items were rated on a 5-point hedonic scale; really bad, bad, neither good or bad, good, or very good. The oral drops were considered acceptable if the mean hedonic scores were ≤3 for each aspect of palatability (taste, aftertaste, smell, and mouthfeel).

    Time frame: assessed at Baseline up to Week 26, Week 26 reported

  13. Number of Participants With Response to the Acceptability Questionnaire

    The acceptability of vortioxetine oral drops was assessed after intake of a single dose (5 to 20 mg) corresponding to the participant's current vortioxetine dose (replacing the vortioxetine tablet on that day). The acceptability assessment was based on 3 items; acceptability of the taste, whether the drops were perceived as easy to take, willingness to take the drops every day (provided it was the only available formulation). For each item the response options were no, not sure, and yes. The oral drops were considered acceptable if \<60% of participants responded "no" to each of the 3 questions regarding acceptability.

    Time frame: assessed at Baseline up to Week 26, Week 26 reported

07

Results

Posted Dec 28, 2022
Limitations and caveats
The study was terminated early based on new efficacy data from another study.

Participant flow

Participant flow — Overall Study
MilestoneVortioxetine
Started662
Received at least 1 dose of study drug662
Completed526
Not completed136
Withdrew: Adverse event34
Withdrew: Lack of efficacy10
Withdrew: Non-compliance with study drug15
Withdrew: Protocol violation3
Withdrew: Withdrawal by subject20
Withdrew: Lost to follow-up13
Withdrew: Rolled over to 13546a2
Withdrew: Other than specified39

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. SAEs included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAE was defined as an AE that started or increased in intensity on or after the date of first dose of study drug in this study 12712A. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.

Time frame:
Baseline up to Week 30
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsVortioxetine
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)404
SecondaryChange From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 26

CDRS-R consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. Total score ranged from 17 (normal) to 113 (severe depression). Least square (LS) mean was calculated using a restricted maximum likelihood-based mixed model for repeated measurements (MMRM) approach.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 26
units on a scaleVortioxetine
Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 26-16.05 ± 0.63
SecondaryTime to First Relapse

Relapse was defined as a total score ≥40 on the CDRS-R. CDRS-R consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. Total score ranged from 17 (normal) to 113 (severe depression).

Time frame:
Baseline up to Week 26

No measurements were reported for this outcome.

SecondaryTime to First Loss of Remission

Remission was defined as a total score ≤28 on the CDRS-R. CDRS-R consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. Total score ranged from 17 (normal) to 113 (severe depression).

Time frame:
Baseline up to Week 26

No measurements were reported for this outcome.

SecondaryChange From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 26

The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants). LS mean was calculated using a restricted maximum likelihood-based MMRM approach.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 26
units on a scaleVortioxetine
Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 26-1.48 ± 0.06
SecondaryClinical Global Impression - Global Improvement (CGI-I) Score

The CGI-I provides the clinician's impression of the participant's improvement (or worsening). The clinician assesses the participant's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). LS mean was calculated using a restricted maximum likelihood-based MMRM approach.

Time frame:
Week 26
Reported as:
Least squares mean · units on a scale
Clinical Global Impression - Global Improvement (CGI-I) Score
units on a scaleVortioxetine
Clinical Global Impression - Global Improvement (CGI-I) Score1.72 ± 0.04
SecondaryChildren (7-11 Years): Change From Baseline in Behaviour Rating Inventory of Executive Function - Preschool (BRIEF-P) Using the Global Executive Composite (GEC) Score at Week 26

BRIEF form is an 86-item measure with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. For BRIEF-P form, only the first 72 items (Inhibit \[10\], Shift \[8\], Emotional Control \[10\], Initiate \[8\], Working Memory \[10\], Plan/Organize \[12\], Organization of Materials \[6\], Monitor \[8\]) were included in clinical scales. Clinical scales combined to form 2 indexes, Behavioural Regulation Index (BRI) and Metacognition Index (MI), and 1 composite summary score, the GEC, that incorporates all 8 clinical scales. GEC score was calculated as the sum of index scores ranging from 72-216; higher scores indicating greater impairment in executive functions. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-P. Conversion was based on gender and age group. T-scores ranged between 30 to 101, with a lower score indicating better functioning.

Time frame:
Baseline, Week 26
Reported as:
Mean · T score
Children (7-11 Years): Change From Baseline in Behaviour Rating Inventory of Executive Function - Preschool (BRIEF-P) Using the Global Executive Composite (GEC) Score at Week 26
T scoreVortioxetine
Children (7-11 Years): Change From Baseline in Behaviour Rating Inventory of Executive Function - Preschool (BRIEF-P) Using the Global Executive Composite (GEC) Score at Week 26-7.41 ± 11.70
SecondaryAdolescents (12-18 Years): Change From Baseline in Behaviour Rating Inventory of Executive Function - Self-report (BRIEF-SR) Using the GEC Score at Week 26

BRIEF form is an 86-item measure that assesses impairment in executive function with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. For BRIEF-SR form, only 80 items (Inhibit \[13\], Shift \[10\], Emotional Control \[10\], Initiate \[5\], Working Memory \[12\], Plan/Organize \[13\], Organization of Materials \[7\], Monitor \[10\]) were included in clinical scales. Clinical scales combined to form 2 indexes, the BRI and the MI, and 1 composite summary score, the GEC, that incorporates all 8 clinical scales. GEC score was calculated as the sum of index scores and ranges from 80-240 with higher scores indicating greater impairment in functions. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-SR. The conversion was based on gender and the age group. T-scores ranged between 29 to 104, with a lower score indicating better functioning.

Time frame:
Baseline, Week 26
Reported as:
Mean · T score
Adolescents (12-18 Years): Change From Baseline in Behaviour Rating Inventory of Executive Function - Self-report (BRIEF-SR) Using the GEC Score at Week 26
T scoreVortioxetine
Adolescents (12-18 Years): Change From Baseline in Behaviour Rating Inventory of Executive Function - Self-report (BRIEF-SR) Using the GEC Score at Week 26-7.50 ± 13.82
SecondaryChildren (7-11 Years): Change From Baseline in BRIEF-P Using the MI Score at Week 26

BRIEF form is an 86-item measure that assesses impairment in executive function with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. Clinical scales combined to form 2 indexes, the BRI and the MI. For BRIEF-P, MI is comprised of Initiate (8), Working Memory (10), Plan/Organize (12), Organization of Materials (6), and Monitor (8) scales. The MI scores are calculated as the sum of the total 44 items ranging from 44 to 132 with lower scores reflecting better functioning. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-P. The conversion was based on gender and the age group. T-scores ranged between 30 to 98, with a lower score indicating better functioning.

Time frame:
Baseline, Week 26
Reported as:
Mean · T score
Children (7-11 Years): Change From Baseline in BRIEF-P Using the MI Score at Week 26
T scoreVortioxetine
Children (7-11 Years): Change From Baseline in BRIEF-P Using the MI Score at Week 26-7.36 ± 11.98
SecondaryAdolescents (12-18 Years): Change From Baseline in BRIEF-SR Using the MI Score at Week 26

BRIEF form is an 86-item measure that assesses impairment in executive function with symptoms rated on a 3-point likert scale of 1 "never", 2 "sometimes" or 3 "often". These items cover 8 non-overlapping clinical scales. Clinical scales combined to form 2 indexes, the BRI and the MI. For BRIEF-SR, MI is comprised of Working Memory (12), Plan/Organize (13), Organization of Materials (7), and Task Completion (10) scales. The MI scores are calculated as the sum of the total 42 items ranging from 42 to 126 with lower scores reflecting better functioning. Raw scores converted to T-scores as detailed in T-score conversion tables for BRIEF-SR. The conversion was based on gender and the age group. T-scores ranged between 31 to 100, with a lower score indicating better functioning.

Time frame:
Baseline, Week 26
Reported as:
Mean · T score
Adolescents (12-18 Years): Change From Baseline in BRIEF-SR Using the MI Score at Week 26
T scoreVortioxetine
Adolescents (12-18 Years): Change From Baseline in BRIEF-SR Using the MI Score at Week 26-7.18 ± 13.71
SecondaryChange From Baseline in Children's Global Assessment Scale (CGAS) Score at Week 26

The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally-oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The score ranges from 1 (most functionally impaired child) to 100 (the healthiest). A score greater than 70 indicates normal function.

Time frame:
Baseline, Week 26
Reported as:
Mean · units on a scale
Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Week 26
units on a scaleVortioxetine
Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Week 2614.78 ± 14.29
SecondaryChange From Baseline in Pediatric Quality of Life Inventory Present Functioning Visual Analogue Scale (PedsQL VAS) Total Score at Week 26

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using VAS. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The total score is the average of all 6 items ranging from 0 to 10, where a lower value represents a better outcome.

Time frame:
Baseline, Week 26
Reported as:
Mean · units on a scale
Change From Baseline in Pediatric Quality of Life Inventory Present Functioning Visual Analogue Scale (PedsQL VAS) Total Score at Week 26
units on a scaleVortioxetine
Change From Baseline in Pediatric Quality of Life Inventory Present Functioning Visual Analogue Scale (PedsQL VAS) Total Score at Week 26-1.50 ± 1.87
SecondaryNumber of Participants With Response to the Palatability Questionnaire

The palatability of vortioxetine oral drops was assessed after intake of a single dose (5 to 20 mg) corresponding to the participant's current vortioxetine dose (replacing the vortioxetine tablet on that day). The palatability assessment included 4 questions on the overall appreciation of a medicinal product in relation to its taste (What do you think of the taste), mouthfeel (How does medicine feel in your mouth), aftertaste (What do you think of the after taste), and smell (What do you think of the smell). The items were rated on a 5-point hedonic scale; really bad, bad, neither good or bad, good, or very good. The oral drops were considered acceptable if the mean hedonic scores were ≤3 for each aspect of palatability (taste, aftertaste, smell, and mouthfeel).

Time frame:
assessed at Baseline up to Week 26, Week 26 reported
Reported as:
Count of participants · Participants
Number of Participants With Response to the Palatability Questionnaire
ParticipantsVortioxetine
Mouthfeel — Really bad11
Mouthfeel — Bad17
Mouthfeel — Neither good or bad38
Mouthfeel — Good55
Mouthfeel — Very good32
Aftertaste — Really bad13
Aftertaste — Bad26
Aftertaste — Neither good or bad54
Aftertaste — Good32
Aftertaste — Very good28
Smell — Really bad4
Smell — Bad4
Smell — Neither good or bad37
Smell — Good59
Smell — Very good49
Taste — Really bad13
Taste — Bad15
Taste — Neither good or bad33
Taste — Good60
Taste — Very good32
SecondaryNumber of Participants With Response to the Acceptability Questionnaire

The acceptability of vortioxetine oral drops was assessed after intake of a single dose (5 to 20 mg) corresponding to the participant's current vortioxetine dose (replacing the vortioxetine tablet on that day). The acceptability assessment was based on 3 items; acceptability of the taste, whether the drops were perceived as easy to take, willingness to take the drops every day (provided it was the only available formulation). For each item the response options were no, not sure, and yes. The oral drops were considered acceptable if \<60% of participants responded "no" to each of the 3 questions regarding acceptability.

Time frame:
assessed at Baseline up to Week 26, Week 26 reported
Reported as:
Number · participants
Number of Participants With Response to the Acceptability Questionnaire
participantsVortioxetine
Willingness to take the drops every day: No27
Willingness to take the drops every day: Not sure17
Willingness to take the drops every day: Yes109
Easy to take medicine: No8
Easy to take medicine: Neither easy or difficult10
Easy to take medicine: Yes135
Acceptability of the taste: No31
Acceptability of the taste: Not sure24
Acceptability of the taste: Yes98

Adverse events

Collected over Baseline up to Week 30. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vortioxetine0/662 (0%)14/662 (2.1%)255/662 (38.5%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventVortioxetine
Suicidal ideationPsychiatric disorders4/662
Suicide attemptPsychiatric disorders4/662
Intentional overdoseInjury, poisoning and procedural complications3/662
ArthropathyMusculoskeletal and connective tissue disorders1/662
OsteitisMusculoskeletal and connective tissue disorders1/662
TorticollisMusculoskeletal and connective tissue disorders1/662
Psychomotor hyperactivityNervous system disorders1/662
Major depressionPsychiatric disorders1/662
ManiaPsychiatric disorders1/662
Psychogenic seizurePsychiatric disorders1/662
Most frequent other events
Most frequent other events
EventVortioxetine
NauseaGastrointestinal disorders138/662
HeadacheNervous system disorders116/662
VomitingGastrointestinal disorders69/662
Abdominal painGastrointestinal disorders46/662
NasopharyngitisInfections and infestations46/662
DizzinessNervous system disorders38/662

Baseline characteristics

All-patients-treated set (APTS) included all participants who took at least 1 dose of vortioxetine in this study 12712A.

Age, Continuous
Age, Continuous(years)Vortioxetine
Mean12.33 ± 3.07
Age, Customized
Age, Customized(Participants)Vortioxetine
Children (7-11 years)300
Adolescents (12-17 years)352
Adults (18-64 years)10
Sex: Female, Male
Sex: Female, Male(Participants)Vortioxetine
Female361
Male301
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vortioxetine
White447
Black8
Asian5
Other188
Unknown9
Not reported5
08

Study locations

78 sites
  • The University of Arizona Sarver Heart Center (SHC)
    Tucson, Arizona 85724, United States
  • Kansas University School of Medicine-Wichita
    Wichita, Kansas 67214, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • University Hospital Cleveland Medical Center Division of Child and Adolescent Psychiatry
    Cleveland, Ohio 44012, United States
  • MHAT Targovishte AD
    Targovishte, 7700, Bulgaria
  • Diagnostic Consultative Center Mladost-M Varna OOD
    Varna, 9020, Bulgaria
  • Paediatric Sleep Research Inc.
    Toronto, Ontario M5S 3A3, Canada
  • E.S.E. Hospital Mental de Antioquia HOMO
    Bello, Antioquia 51050, Colombia
  • Centro de Investigaciones y Proyectos en Neurociencias CIPNA LTDA IPS.
    Barranquilla, Atlantico 80020, Colombia
  • Centro de investigaciones del Sistema Nervioso SAS Grupo CISNE SAS
    Bogota, DC 111166, Colombia
  • Psynapsis Salud Mental S.A.
    Pereira, Risaralda, Colombia
  • Marienthali Kliinik
    Tallinn, 11315, Estonia
  • Cabinet Psyche
    Douai, Nord 59500, France
  • Centre Medical Ambroise Pare
    Elancourt, 78990, France
  • CHU de Nantes - Hopital Hotel Dieu
    Nantes Cedex 1, 44093, France
  • Univ. Freiburg
    Freiburg, Baden-Wurttemberg 79104, Germany
  • Rheinhessen-Fachklinik Mainz, Kinder und Jugendpsychiatri
    Mainz, 55122, Germany
  • Klinik fur Kinderneurologie und Sozialpadiatrie Kinderzentrum Maulbronn gGmbH
    Maulbronn, 75433, Germany
  • University Hospital Tuebingen -
    Tuebingen, 72076, Germany
  • Vadaskert Child Psychiatric Hospital and Outpatient
    Budapest, 1021, Hungary
  • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
    Gyula, 5700, Hungary
  • Ramat Chen - Mental Health Clinic
    Tel Aviv, 6435807, Israel
  • Scientific Institute Fondazione Stella Maris
    Calambrone, Pisa 56026, Italy
  • Sciaf Ulss 16 Padova
    Padova, Regione Veneto 35143, Italy
  • Hospital Trust-University of Cagliari
    Cagliari, 09121, Italy
  • U.O.C. Neuropsichiatria Infantile - IRCCS Istituto Giannina Gaslini
    Genova, 16147, Italy
  • Dip.Sc.Biomediche, Odont. e Imm.Funz.li, AOU Policlinico G. Martino
    Messina, 98125, Italy
  • University Federico II Of Naples
    Napoli, 80131, Italy
  • Soon Chun Hyang University Hospital Cheonan
    Cheonan-si, Chungcheongnam-do 31151, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Hospital Gintermuiza
    Jelgava, 3008, Latvia
  • Linda Keruze's Psychiatric Center, LLC
    Liepaja, LV-3401, Latvia
  • Children Hospilal -Gailezers
    Riga, 1079, Latvia
  • Sigulda Hospital Outpatient Clinic
    Sigulda, LV-2150, Latvia
  • Instituto Nacional de Pediatria (INP) (National Institute of Pediatrics)
    Ciudad de Mexico, Distrito Federal 04530, Mexico
  • Clinica Cemelli
    Guadalajara, Jalisco 44200, Mexico
  • Roberto Zepeda Sanchez
    Guadalajara, Jalisco 44690, Mexico
  • CRI Centro Regiomontano de Investigacion SC
    Monterrey, Nuevo Leon 64000, Mexico
  • Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C
    Culiacan De Rosales, Sinaloa 80230, Mexico
  • B & B Investigaciones Medicas, SC
    Mazatlan, Sinaloa 82140, Mexico
  • BIND Investigaciones S.C
    San Luis Potosi, 78213, Mexico
  • Prywatne Gabinety Lekarskie Promedicus
    Bialystok, Podlaskie 15879, Poland
  • Centrum Badan Klinicznych PI-House Sp. z o.o.
    Gdansk, 80-546, Poland
  • Przychodnia Syntonia Poradnia Zdrowia Psychicznego
    Kielce, 25-103, Poland
  • Spectrum Centrum Psychiatrii Specjalistyczny Gabinet Psychiatryczny
    Lublin, 20-884, Poland
  • Filip Rybakowski Specjalistyczna Praktyka Lekarska
    Poznan, 60-744, Poland
  • Specjalistyczny Szpital im. dra A. Sokolowskiego w Walbrzychu
    Walbrzych, 58300, Poland
  • Centrum Neuropsychiatrii Neuromed
    Wroclaw, 54-235, Poland
  • Medicorehabilitation Research Center Phoenix
    Rostov-On-Don, Rostov State 344010, Russian Federation
  • Stavropol Region Psychiatric Hospital No.2
    Stavropol, Stavropol Region 357034, Russian Federation
  • Arkhangelsk Regional Clinical Mental Hospital
    Arkhangelsk, 163530, Russian Federation
  • State Budgetary Healthcare Institution of Sverdlovsk Region ¿Sverdlovsk Regional Clinical Psychi...
    Ekaterinburg, 620030, Russian Federation
  • GUZ Engels Psychiatric Hospital
    Engels, 413124, Russian Federation
  • State Budgetary Healthcare Institution (SBHI) Specialized Clinical Psychiatric Hospital 1 of the ...
    Krasnodar, 350007, Russian Federation
  • Lipetsk Regional Psychoneurological Hospital
    Lipetsk, 398007, Russian Federation
  • Nizhny Novgorod Region State Institution Of Healthcare Clinical Psychiatric Hospital 1 Of Nizhny ...
    Nizhny Novgorod, 603155, Russian Federation
  • LLC City Neurological Center Sibneuromed
    Novosibirsk, 630091, Russian Federation
  • Rostov State Medical University of the Minzdravsotsrazvitiya of Russia
    Rostov-on-Don, 344022, Russian Federation
  • Saratov State Medical University
    Saratov, 410028, Russian Federation
  • Guz Saratov Regional Psychiatric Hospital St. Sofii
    Saratov, 410060, Russian Federation
  • City Psychiatric Hospital No.3 named after I.I. Skvortsov-Stepanov
    St-Petersburg, 197341, Russian Federation
  • Nebbiolo LLC
    Tomsk, 634009, Russian Federation
  • Yaroslavl Regional Clinical Psychiatry Hospital
    Yaroslavl, 150003, Russian Federation
  • Child and Adolescent Neurology and Psychiatry Clinic
    Belgrade, 11000, Serbia
  • Institute of Mental Health
    Belgrade, 11000, Serbia
  • University Clinical Center Kragujevac
    Kragujevac, 34000, Serbia
  • Clinical Center of Vojvodina - Clinic of Psychiatry
    Novi Sad, 21000, Serbia
  • Daily Hospital for Children and Adolescents
    Pantelej-Nis, 18000, Serbia
  • Cape Trial Centre
    Bellville, Cape Town 7530, South Africa
  • Hospital Universitario Fundacion Alcorcon
    Alcorcon, Madrid 28922, Spain
  • Unidad de Salud Mental Infanto-Juvenil (USMI-J) Edificio de Consultas Externas. Hospital MarAtimo
    Torremolinos, Malaga 29620, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28009, Spain
  • Ukrainian Research Institute Of Social, Forensic Psychiatry And Drug Abuse, Kiev City Psychoneuro...
    Kyiv, 04080, Ukraine
  • Odessa Regional Medical Centre of Mental Health
    Odessa, 65006, Ukraine
  • Maltsev Poltava Regional Clinical Psychiatric Hospital, Higher State Educational Institution Of U...
    Poltava, 36013, Ukraine
  • Ternopil Regional Clinical Municipal Psycho-Neurological Hospital, Ternopil State Medical Univers...
    Ternopil, 46000, Ukraine
  • NHS Greater Glasgow and Clyde Glasgow Clinical Research Facility-Queen Elizabeth University Hospi...
    Glasgow, G51 4TF, United Kingdom
  • Alder Hey Hospital
    Liverpool, L12 2AP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Mar 2022, 67 months.

Results were first posted in Dec 2022, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2016
First posted
Aug 18, 2016
StartActual
Aug 17, 2016
Primary completionActual
Mar 25, 2022
CompletionActual
Apr 19, 2022
Results first posted
Dec 28, 2022
Last update
Dec 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02871297
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Aug 18, 2016
Start date
Aug 17, 2016
Primary completion
Mar 25, 2022
Completion
Apr 19, 2022
Results posted
Dec 28, 2022
Last update
Dec 28, 2022

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion